Loading stock data…
Anteris Technologies Global Corp (AVR)
$9.78+0.09 (+0.93%)
Market ClosedLast close Jun 29
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Anteris Technologies Global Corp. in the Healthcare sector is trading at $9.78 with a market capitalization of $905M. Wall Street consensus targets $15.33 (3 analysts), implying a +56.8% move over the next 12 months. The stock is currently near its 52-week high of $10.56, remaining 66.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +56.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $768,981 |
| Gross Profit | — | — | — | — | $325,435 |
| Operating Income | — | — | — | — | -$20.60M |
| Net Income | — | — | — | — | -$21.86M |
Peer Comparison
JNJUNHPFE
Fundamentals
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$905.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
1.47M
Recent News
France clearance marks key milestone for Anteris' pivotal PARADIGM Trial
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full regulatory clearance from France's National Agency for Medicines and Health Products Safety (ANSM) for its global pivotal PARADIGM Trial, paving the way for patient recruitment to begin at leading French cardiac centres. This...
Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has strengthened its board with the appointments of experienced healthcare and finance executive Susan Knight and company veteran Stephen Denaro as directors. Knight joins as a Class I director, serving through to the company’s 2028 annual...
Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported strong operational progress for the March 2026 quarter as the company advanced recruitment for its global PARADIGM pivotal trial and strengthened its balance sheet with US$320 million in capital raises. The structural heart...
Anteris treats first US patients in DurAVR pivotal trial
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has enrolled and successfully treated the first US patients in the global pivotal trial of its DurAVR® Transcatheter Heart Valve (THV) for severe calcific aortic stenosis. The procedures were carried out by Dr Azeem Latib at Montefiore...